论文部分内容阅读
目的:评价含米托蒽醌的联合化疗方案(HAM) 治疗老年急性髓系白血病(AML) 。方法:比较应用HAM 方案治疗老年AML36 例与标准DA 方案治疗老年AML23 例及HAM 方案治疗中青年AML53 例的治疗效果。结果:(1)HAM 方案治疗老年AML 与DA 方案比较两者CR 率无显著性差异,但HAM 方案可使患者缓解迅速且中位缓解期较DA 方案长;(2)HAM 方案治疗老年AML 较年轻患者CR 率低且缓解期短;(3) 米托蒽醌主要毒性作用为骨髓抑制HAM 方案诱导相关死亡率并无增高。结论:HAM 方案可作为老年AML 的一种较好的治疗方案。
OBJECTIVE: To evaluate the combination therapy with mitoxantrone (HAM) in the treatment of elderly acute myeloid leukemia (AML). METHODS: The therapeutic effects of HAM regimen in the treatment of 36 elderly AML patients and the standard DA regimen in the treatment of senile AML in 23 patients and HAM regimen in the treatment of 53 young AML patients were compared. Results: (1) There was no significant difference in the CR rate between the HAM regimen and the DA regimen for elderly patients, but the HAM regimen made the patient’s remission more rapid and the median remission period longer than that of the DA regimen; (2) The HAM regimen was effective in treating elderly AML patients. The CR rate in young patients is low and the remission period is short; (3) The main toxic effect of mitoxantrone is no increase in the relative mortality induced by the myelosuppressive HAM regimen. Conclusion: The HAM regimen can be used as a better treatment option for elderly AML.